Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden

Bodour Salhia,David Fabrizio,Filip Janku,Funda Meric‐Bernstam,Haeseong Park,Helen J. Huang,Ignacio Garrido‐Laguna,Jason R. Westin,Jeffrey S. Ross,Jo‐Anne Vergilio,Michelle A. Fanale,Philip J. Stephens,Vincent A. Miller,Winnie S. Liang,Yasuhiro Oki

A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa,Imane El Dika,Manish R. Sharma,Martin E. Gutierrez,Matthew L. Sherman,Mohamedtaki A. Tejani,Olugbenga O. Olowokure,Rebecca A. Miksad,Shuchi S. Pandya,Stephen Williamson

Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome

Andrew W. Hahn,Neeraj Agarwal,Sumanta K. Pal

Use of Antidepressant Medications Moderates the Relationship Between Depressive Symptoms and Hospital Length of Stay in Patients with Advanced Cancer

Areej El‐Jawahri,Barbara J. Cashavelly,Charn‐Xin Fuh,Daniel E. Lage,David P. Ryan,Ephraim P. Hochberg,Jennifer S. Temel,Joseph A. Greer,Kelly E. Irwin,Lara Traeger,P. Connor Johnson,Risa L. Wong,Ryan D. Nipp,Sara M. D'Arpino,Vicki A. Jackson,William F. Pirl

Barriers and Facilitators to Cervical Cancer Screening, Diagnosis, Follow‐Up Care and Treatment: Perspectives of Human Immunodeficiency Virus‐Positive Women and Health Care Practitioners in Tanzania

Alaya Koneru,Eric A. Aris,Julius D. Mwaiselage,Lori Brand Bateman,Nedra F. Lisovicz,Pauline E. Jolly,Renicha McCree,Safina Yuma,Shaundra Blakemore,Thereza Mtesigwa

A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma

Bhumsuk Keam,Dae Seog Heo,Dong‐Wan Kim,Jin Chul Paeng,Kyung Chul Moon,Miso Kim,Tae Min Kim,Yu Jung Kim

A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)

Chi Hoon Maeng,Dae Young Zang,Hong Suk Song,In Gyu Hwang,Jae Yong Cho,Jin Won Kim,Joo Seop Chung,Keun‐Wook Lee,Sang Cheul Oh,Su Jin Jeong,Tae‐You Kim,Yeul Hong Kim

Immuno‐Oncology in China

Bruce A. Chabner,Shun Lu

Patient‐Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia

Amir Fathi,Andrew Brunner,Areej El‐Jawahri,Daniel DeAngelo,David P. Steensma,Gabriela Hobbs,Gregory A. Abel,Harry VanDusen,Jennifer S. Temel,Joseph A. Greer,Julia Foster,Lara Traeger,Margaret Nelson‐Lowe,Martha Wadleigh,Philip Amrein,Richard M. Stone,Thomas W. LeBlanc,Zhigang Li

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors

Shun Lu,Yi Yang,Yongfeng Yu

Biomarkers for Programmed Death‐1 Inhibition in Prostate Cancer

Alexander W. Wyatt,Brian Lewis,Charlotte Manogue,Elisa Ledet,Oliver Sartor,Patrick Cotogno

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy

Amna Ibrahim,Amy E. McKee,Daniel L. Suzman,Jason Schroeder,Julia A. Beaver,Kirsten B. Goldberg,Laura L. Fernandes,Rajeshwari Sridhara,Richard Pazdur,Shenghui Tang,Stella Karuri,Sundeep Agrawal,V. Ellen Maher,Yang‐min Ning

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer

Emmanuel S. Antonarakis

Numbers Have Life: A Commentary on “Predictors of Survival in Patients with Advanced Gastrointestinal Malignancies Admitted to the Intensive Care Unit”

Aminah Jatoi,Jennifer G. Le‐Rademacher

Permanent Chemotherapy‐Induced Alopecia in Patients with Breast Cancer: A 3‐Year Prospective Cohort Study

Danbee Kang,Dong‐Youn Lee,Eliseo Guallar,Eun‐Kyung Choi,Hae Kwang Lee,Im‐Ryung Kim,Jeong Eon Lee,Jin Seok Ahn,Ji‐Hye Park,Juhee Cho,Mario E. Lacouture,Seok Jin Nam,Yeon Hee Park,Young Hyuck Im

You and Whose Army?

Mark A. Lewis

Association of Modified‐FOLFIRINOX‐Regimen‐Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population

Chengxiang Guo,Guogang Li,Jianying Lou,Pintong Huang,Qi Zhang,Qichun Wei,Qinghai Li,Risheng Que,Risheng Yu,Shumei Wei,Shunliang Gao,Tao Ma,Tingbo Liang,Xiang Li,Xueli Bai,Yinan Shen,Ying Yuan,Yiwen Chen

First‐in‐Human Phase I Study of MBC‐11, a Novel Bone‐Targeted Cytarabine‐Etidronate Conjugate in Patients with Cancer‐Induced Bone Disease

Alexander Alexandrov,Alexander Karpeisky,Daniel D. Von Hoff,Larisa Plekhova,Shawn Patrick Zinnen

Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M‐Positive Non‐Small‐Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial

Akira Nakao,Chikara Sakaguchi,Hidetaka Uramoto,Hisao Imai,Junji Uchino,Keita Nakatomi,Kenichi Yoshimura,Kiyoaki Uryu,Koichi Takayama,Masaki Fujita,Masaya Akai,Masayuki Kawasaki,Minoru Fukuda,Noboru Hattori,Nobuyo Tamiya,Noriya Hiraoka,Osamu Hiranuma,Seiji Nagashima,Tadaaki Yamada,Tadashi Mio,Takako Mouri,Tamotsu Ishizuka,Toshihide Yokoyama,Toshiyuki Kita,Yasuhiro Goto,Yasuki Uchida,Yoshiko Kaneko,Yusuke Chihara,Yutaka Kubota

Role of Family Obligation Stress on Ugandan Women's Participation in Preventive Breast Health

Benjamin O. Anderson,Beti Thompson,Daniel S. Hippe,Donald L. Patrick,Gertrude Nakigudde,John R. Scheel,Julie R. Gralow,Scott Parker,Yamile Molina

Hematologic Complications of Immune Checkpoint Inhibitors

Arissa Young,Benedicte Lebrun‐Vignes,Douglas B. Johnson,Elizabeth J. Davis,Javid J. Moslehi,Jennifer R. Green,Joe‐Elie Salem,Kristin K. Ancell,P. Brent Ferrell

A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)

Ann E. McCullough,George P. Kim,Jeffrey P. Meyers,Jeffrry P. Jaffe,Matthew M. Ames,Nathan R. Foster,Steven R. Alberts,Thomas C. Smyrk,Thorvardur R. Halfdanarson

Endostatin and Oxaliplatin‐Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study

Ni Zhang,Peng Chen,Shixiu Wu,Tao Song,Wenxin Li

PD‐1 Pandemonium at the American Association for Cancer Research Annual Meeting

Susan E. Bates

Adjuvant Zoledronic Acid in High‐Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial

Astrid Lipplaa,Hans Gelderblom,Judith R. Kroep,Lizz van der Heijden,Pancras C.W. Hogendoorn,Paul C. Jutte,Sander Dijkstra

Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti‐Epidermal Growth Factor Receptor‐Induced Acne‐Like Rash: A Randomized Left‐Right Comparative Evaluation (APPEARANCE)

Atsushi Fukunaga,Atsushi Kawaguchi,Chikako Nishigori,Hironobu Minami,Hisayo Doi,Kazutoshi Tobimatsu,Kazuyuki Kobayashi,Kei Takenaka,Ken Washio,Kyosuke Nakata,Masanori Toyoda,Masatsugu Yamamoto,Motoko Tachihara,Naho Marugami,Naoko Chayahara,Naomi Kiyota,Naomi Mizuta,Toru Mukohara,Yoshihiro Nishimura,Yoshimi Fujishima

Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma

Hiroaki Yanagimoto,Kenji Nakagawa,Kota Nakamura,Masayuki Sho,Minako Nagai,Naoya Ikeda,Satoshi Hirooka,Satoshi Nishiwada,So Yamaki,Sohei Satoi,Takahiro Akahori,Tomohisa Yamamoto

An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma

Baek‐Yeol Ryoo,Bradley Freilich,Chia‐Chi Lin,Ghassan K. Abou‐Alfa,Ho Yeong Lim,Hye Jin Choi,Imane El Dika,Jennifer Knox,Joanne Brown,Jung‐Hwan Yoon,Manuel Modiano,Robin K. Kelley,Thomas Yau,Tsu‐Yi Chao,Wei Peng Yong

A First‐in‐Human Phase I Study of GC1118, a Novel Anti‐Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors

Do‐Youn Oh,Howard Lee,Jin Won Kim,Jonghwa Won,Jung‐Won Shin,Keun‐Wook Lee,Sae‐Won Han,Seokyung Hahn,Seong‐Jin Jo,Woo Ho Kim,Yung‐Jue Bang

Patient‐Friendly Language to Facilitate Treatment Choice for Patients with Cancer

Janice Kim,Jennifer Gao,Julia A. Beaver,Laleh Amiri‐Kordestani,Paul Kluetz

Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis

Angela Tramontano,Ayman Ali,Carlos Fernandez‐Del Castillo,Chin Hur,Chung Yin Kong,Cristina R. Ferrone,David P. Ryan,Deborah Schrag,Emily C. Dowling,Jin G. Choi,Pari Pandharipande,Ryan D. Nipp,Theodore S. Hong,Tiannan Zhan

A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors

Amol Tendolkar,Dong Xu,Hongyun Zhao,Jennifer Sheng,Li Zhang,Lu Chen,Shaodong Hong,Wenfeng Fang,Yang Zhang,Yuanyuan Zhao,Yunpeng Yang,Yuxiang Ma

In Memoriam: Patrick G. Johnston (1958–2017)

Bruce A. Chabner

Publish or Perish v2

Susan E. Bates

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

David F. McDermott,M. Dror Michaelson,Xin Gao

Phase II Study of Dehydroepiandrosterone in Androgen Receptor‐Positive Metastatic Breast Cancer

Alessandra Gennari,Alessandro Saba,Alessio Schirone,Andrea Rocca,Beatrice Campi,Caterina Donati,Daniele Andreis,Dino Amadori,Elisabetta Petracci,Elisabetta Pietri,Enrico Campadelli,Federico Piacentini,Francesco Fabbri,Ilaria Massa,Linda Valmorri,Lorenzo Gianni,Maria Maddalena Tumedei,Mario Nicolini,Sara Bravaccini,Sara Ravaioli

Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer

Ann W. Gramza,Jaydira Del Rivero,Jean Ward,Maureen Edgerly,Ravi A. Madan,Sanjeeve Balasubramaniam,Tito Fojo

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors

Afshin Eli Gabayan,Albert Assad,Daniel D. Von Hoff,Gregory L. Beatty,Huiling Zhen,Julie Switzky,Nikhil Uppal,Ross Donehower,Safi Shahda,Steven J. Cohen,Thaddeus Beck

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match

Razelle Kurzrock,Vivek Subbiah

FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1

Amy E. McKee,Huanyu Chen,Janaki Veeraraghavan,Kirsten B. Goldberg,Kun He,Lola Fashoyin‐Aje,Martha Donoghue,Patricia Keegan,Richard Pazdur

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study

Aiqin Gu,Baohui Han,Bo Jing,Chunlei Shi,Hao Bai,Heng Zhao,Hua Zhong,Huiming Wang,Jianxing Shi,Jiayuan Sun,Jie Shen,Jie Zhang,Junyi Ye,Junyuan Wang,Liwen Xiong,Liyan Jiang,Rong Li,Weiyan Zhang,Wentao Fang,Yuqing Lou

A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer

Chihoko Takahata,Eri Hotta,Hiroya Taniguchi,Kazuhiro Shimomura,Kei Muro,Kyoko Kato,Makiko Kobara,Masahiro Tajika,Naoya Hashimoto,Sachiyo Onishi,Seiichiro Mitani,Shigenori Kadowaki,Shinji Takahashi,Toshiki Masuishi,Yukiya Narita

Phase II Trial of 5‐Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer

Hiroto Ueda,Hisato Kawakami,Kazuhiko Nakagawa,Masayuki Takeda,Naoki Takegawa,Takao Tamura,Takayuki Takahama,Tatsuya Okuno,Yasutaka Chiba,Yoshikane Nonagase

The Metastatic Spine Disease Multidisciplinary Working Group Algorithms

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors

Chris Liang,Cynthia C. Chua,Gary Dukart,Hendrik‐Tobias Arkenau,Johanna C. Bendell,Kathleen N. Moore,Kim Harrow,Manish R. Patel

Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs

Brian Lewis,Charles Ryan,Jodi L. Layton,Oliver Sartor,Tomasz M. Beer

Somebody Tell Me

Sherry‐Ann Brown

PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions

Liliang Xia,Ying Wang,Yuanyong Liu

The Role of Radiation Oncology in Immuno‐Oncology

Jinming Yu,Lian Yang,Ligang Xing,Rui Feng,Xiangjiao Meng

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges

Shukui Qin,Xiufeng Liu